X4 治疗稀有WHIM综合症的药品,欧洲监管机构接受其审查。 X4 Pharmaceuticals' drug for rare WHIM syndrome accepted for review by European regulator.

X4 药品公司提出的治疗WHIM综合症的混合疗法申请已被欧洲药品局接受,以供审查。 X4 Pharmaceuticals' application for mavorixafor, a treatment for WHIM syndrome, has been accepted for review by the European Medicines Agency (EMA). 2024年4月,美国X4公司与美国Norgine公司合作,在欧洲、澳大利亚和新西兰进行该药物的商业化,此后,如果获得批准,它将成为欧洲第一种WHIM综合症的药物。 If approved, it would be the first drug for WHIM syndrome in Europe, following its April 2024 approval in the U.S. X4 has partnered with Norgine for the drug's commercialization in Europe, Australia, and New Zealand. WHIM综合症是一种罕见的免疫紊乱症,影响到欧洲约1 000人。 WHIM syndrome is a rare immune disorder affecting roughly 1,000 people in Europe.